What is the 13F Pro Quality Score for REPL?

13F Pro ranks Replimune Group, Inc. (REPL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View REPL's current score at https://13fpro.ai/research/REPL (free sign-up required for the full ranking).

Which hedge funds own the most REPL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of REPL include BAKER BROS. ADVISORS, RTW INVESTMENTS,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/REPL as soon as new 13F filings post.

Where does 13F Pro source REPL data?

All Replimune Group, Inc. fundamentals and ownership data come directly from SEC EDGAR. Replimune Group, Inc. files with the SEC under CIK 1737953. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is REPL in?

Replimune Group, Inc. (REPL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is REPL research updated on 13F Pro?

REPL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Replimune Group, Inc.(REPL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1737953 REPL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

REPL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Replimune Group, Inc. (REPL), a Healthcare sector company. REPL is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2026), Replimune Group, Inc. reports net income of $-73.2M, free cash flow of $-56.2M. Top institutional holders of REPL by reported 13-F value include BAKER BROS. ADVISORS, RTW INVESTMENTS,, BlackRock,, based on the most recent SEC filings. REPL trades on the Nasdaq exchange and files with the SEC under CIK 1737953. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate REPL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Replimune Group, Inc. directly from SEC EDGAR.

Net Income

Q4 2026

$-73.2M

Free Cash Flow

Q4 2026

$-56.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-45.5% YoY

$-313.9MFY 2026

FY22 $-118.0MFY23 $-174.3MFY24 $-215.8MFY26 $-313.9M

Operating Income

-36.3% YoY

$-319.9MFY 2026

FY22 $-118.3MFY23 $-177.1MFY24 $-234.8MFY26 $-319.9M

EPS (Diluted)

-4.3% YoY

$-3.38FY 2026

FY22 $-2.26FY23 $-2.99FY24 $-3.24FY26 $-3.38

Total Assets

-31.8% YoY

$332.4MFY 2026

FY22 $461.2MFY23 $646.6MFY24 $487.7MFY26 $332.4M

Total Debt

+85.9% YoY

$83.3MFY 2026

FY22 $0.00FY23 $28.6MFY24 $44.8MFY26 $83.3M

Op. Cash Flow

-51.2% YoY

$-280.3MFY 2026

FY22 $-82.2MFY23 $-128.1MFY24 $-185.5MFY26 $-280.3M

Metric	FY 2026	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-313.9M -45.5%	$-215.8M -23.8%	$-174.3M -47.7%	$-118.0M -46.0%	$-80.9M -53.7%	$-52.6M
Operating Income	$-319.9M -36.3%	$-234.8M -32.6%	$-177.1M -49.7%	$-118.3M -48.0%	$-80.0M -42.3%	$-56.2M
EPS (Diluted)	$-3.38 -4.3%	$-3.24 -8.4%	$-2.99 -32.3%	$-2.26 -29.1%	$-1.75	—
Total Assets	$332.4M -31.8%	$487.7M -24.6%	$646.6M +40.2%	$461.2M -15.1%	$543.1M +132.0%	$234.1M
Total Debt	$83.3M +85.9%	$44.8M +56.4%	$28.6M	$0.00	—	$9.8M
Operating Cash Flow	$-280.3M -51.2%	$-185.5M -44.8%	$-128.1M -55.8%	$-82.2M -33.9%	$-61.4M -1.4%	$-60.6M

AI Insight: REPL Financial Trends

Replimune is pre-revenue and burning cash at an accelerating rate, with equity down 61% since Q2 2024 and debt nearly doubled in Q1 2026.

• Operating losses widened from $57M in Q2 2024 to $90M in Q2 2025, then moderated to $72M in Q4 2025 and $73M in Q1 2026.

• Operating cash burn deteriorated from $49M in Q2 2024 to $81M in Q3 2025, slightly improving to $56M in Q1 2026.

• Shareholder equity collapsed 61% from $426M (Q2 2024) to $166M (Q1 2026), while debt remained stable near $46M until Q1 2026 spike to $83M.

⚠ Debt jumped 77% in Q1 2026 to $83M; coupled with 61% equity decline, leverage ratio now critically elevated for pre-revenue biotech.

⚠ No revenue reported across entire period. Cash runway appears limited absent financing or near-term clinical/commercial inflection.

AI Insight: REPL Ratio Trends

Replimune is burning cash with accelerating losses; ROE collapsed to -176% in Q1 2026 while leverage nearly quintupled.

• ROE deteriorated sharply from -50.4% in Q2 2024 to -176.3% in Q1 2026, a 126pp decline over 9 quarters.

• ROA worsened from -40.2% in Q2 2024 to -88.1% in Q1 2026, indicating deepening asset inefficiency.

• Debt-to-equity ratio jumped from 0.11 in Q2 2024 to 0.50 in Q1 2026, a 355% increase in leverage.

⚠ D/E more than doubled from 0.23 in Q4 2025 to 0.50 in Q1 2026—greatest quarter-on-quarter spike in dataset.

⚠ No ROIC data for last three quarters; operating margin and NPM absent throughout suggest unprofitable/pre-revenue stage.

Get alerted when REPL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Replimune Group, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of REPL

BAKER BROS. ADVISORS LP
$84.5M11,045,336 sh
RTW INVESTMENTS, LP
$56.3M7,356,916 sh
BlackRock, Inc.
$47.7M6,239,239 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$32.3M4,221,836 sh
STATE STREET CORP
$28.9M3,782,237 sh
FCPM III SERVICES B.V.
$21.5M2,808,368 sh
VANGUARD CAPITAL MANAGEMENT LLC
$21.1M2,759,120 sh
D. E. Shaw & Co., Inc.
$17.9M2,336,528 sh
GOLDMAN SACHS GROUP INC
$17.4M2,277,276 sh
FMR LLC
$15.6M2,045,490 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$84.5M	11,045,336
RTW INVESTMENTS, LP	$56.3M	7,356,916
BlackRock, Inc.	$47.7M	6,239,239
SUVRETTA CAPITAL MANAGEMENT, LLC	$32.3M	4,221,836
STATE STREET CORP	$28.9M	3,782,237
FCPM III SERVICES B.V.	$21.5M	2,808,368
VANGUARD CAPITAL MANAGEMENT LLC	$21.1M	2,759,120
D. E. Shaw & Co., Inc.	$17.9M	2,336,528
GOLDMAN SACHS GROUP INC	$17.4M	2,277,276
FMR LLC	$15.6M	2,045,490

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put REPL on your watchlist

Track score changes the day Replimune Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is REPL a good stock to buy?

13F Pro's AI-powered analysis of Replimune Group, Inc. (REPL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for REPL are available on the REPL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own REPL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling REPL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Replimune Group, Inc.'s investment landscape.